J Clin Psychiatry:SSRIs暴露会增加年轻患者的卒中风险

2017-10-15 佚名 大话精神

暴露于选择性5-羟色胺再摄取抑制剂(SSRIs)会增加中风的风险。在本研究中,研究人员评估了年龄和时间效应对暴露于SSRI的成年患者首次中风发作的风险。

暴露于选择性5-羟色胺再摄取抑制剂(SSRIs)会增加中风的风险。在本研究中,研究人员评估了年龄和时间效应对暴露于SSRI的成年患者首次中风发作的风险。

方法

研究人员对台湾全国健康保险研究数据库8年的研究结果进行分析。在2001年1月1日至2007年12月31日期间,如果患者至少连续2个月接受SSRIs类药物,则符合研究标准,定义为SSRI暴露者。否则归为SSRI非暴露者。中风诊断依据ICD-9中出血性中风和缺血性中风判断。

结果

1)Kaplan-Meier生存分析显示,在SSRI暴露组中,首次中风发作的可能性显着大于SSRI非暴露组(P < 0.001)。

2)SSRI暴露组的高发病率持续了3年。

3)SSRI暴露者在前三年,缺血性/出血性卒中累积发生率也较高。

4)调整风险比分析表明,年轻的SSRI暴露者更容易发生中分,而大于65岁的人群其中风风险略有增加。

5)缺血性卒中和出血性卒中的分层分析也有类似的风险比趋势。

结论

使用SSRIs可独立增加跨年龄层的卒中风险。在较年轻的成人受试者中,中风风险较高,且多为缺血性卒中。中风的潜在机制可能与脑微出血或止血功能的过度矫正有关。

原始出处:

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1792092, encodeId=c70e1e92092ba, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Nov 03 07:31:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281256, encodeId=78dd1281256f3, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525692, encodeId=e1e7152569211, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545465, encodeId=cd2b15454654f, content=<a href='/topic/show?id=61d416e15a9' target=_blank style='color:#2F92EE;'>#SSRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16715, encryptionId=61d416e15a9, topicName=SSRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ea13741643, createdName=ms7474195563676018, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253352, encodeId=6bb625335256, content=5-ht会卒中?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Oct 16 09:11:46 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253287, encodeId=a2b325328ed9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 16 06:33:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253261, encodeId=e59a25326150, content=加大研究力度.造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cee2018203, createdName=1e207054m17(暂无匿称), createdTime=Mon Oct 16 02:08:59 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253244, encodeId=6c8725324475, content=不错学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Oct 16 00:08:15 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1792092, encodeId=c70e1e92092ba, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Nov 03 07:31:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281256, encodeId=78dd1281256f3, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525692, encodeId=e1e7152569211, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545465, encodeId=cd2b15454654f, content=<a href='/topic/show?id=61d416e15a9' target=_blank style='color:#2F92EE;'>#SSRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16715, encryptionId=61d416e15a9, topicName=SSRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ea13741643, createdName=ms7474195563676018, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253352, encodeId=6bb625335256, content=5-ht会卒中?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Oct 16 09:11:46 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253287, encodeId=a2b325328ed9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 16 06:33:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253261, encodeId=e59a25326150, content=加大研究力度.造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cee2018203, createdName=1e207054m17(暂无匿称), createdTime=Mon Oct 16 02:08:59 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253244, encodeId=6c8725324475, content=不错学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Oct 16 00:08:15 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1792092, encodeId=c70e1e92092ba, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Nov 03 07:31:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281256, encodeId=78dd1281256f3, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525692, encodeId=e1e7152569211, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545465, encodeId=cd2b15454654f, content=<a href='/topic/show?id=61d416e15a9' target=_blank style='color:#2F92EE;'>#SSRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16715, encryptionId=61d416e15a9, topicName=SSRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ea13741643, createdName=ms7474195563676018, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253352, encodeId=6bb625335256, content=5-ht会卒中?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Oct 16 09:11:46 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253287, encodeId=a2b325328ed9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 16 06:33:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253261, encodeId=e59a25326150, content=加大研究力度.造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cee2018203, createdName=1e207054m17(暂无匿称), createdTime=Mon Oct 16 02:08:59 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253244, encodeId=6c8725324475, content=不错学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Oct 16 00:08:15 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1792092, encodeId=c70e1e92092ba, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Nov 03 07:31:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281256, encodeId=78dd1281256f3, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525692, encodeId=e1e7152569211, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545465, encodeId=cd2b15454654f, content=<a href='/topic/show?id=61d416e15a9' target=_blank style='color:#2F92EE;'>#SSRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16715, encryptionId=61d416e15a9, topicName=SSRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ea13741643, createdName=ms7474195563676018, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253352, encodeId=6bb625335256, content=5-ht会卒中?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Oct 16 09:11:46 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253287, encodeId=a2b325328ed9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 16 06:33:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253261, encodeId=e59a25326150, content=加大研究力度.造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cee2018203, createdName=1e207054m17(暂无匿称), createdTime=Mon Oct 16 02:08:59 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253244, encodeId=6c8725324475, content=不错学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Oct 16 00:08:15 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1792092, encodeId=c70e1e92092ba, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Nov 03 07:31:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281256, encodeId=78dd1281256f3, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525692, encodeId=e1e7152569211, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545465, encodeId=cd2b15454654f, content=<a href='/topic/show?id=61d416e15a9' target=_blank style='color:#2F92EE;'>#SSRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16715, encryptionId=61d416e15a9, topicName=SSRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ea13741643, createdName=ms7474195563676018, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253352, encodeId=6bb625335256, content=5-ht会卒中?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Oct 16 09:11:46 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253287, encodeId=a2b325328ed9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 16 06:33:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253261, encodeId=e59a25326150, content=加大研究力度.造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cee2018203, createdName=1e207054m17(暂无匿称), createdTime=Mon Oct 16 02:08:59 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253244, encodeId=6c8725324475, content=不错学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Oct 16 00:08:15 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
    2017-10-16 sunfeifeiyang

    5-ht会卒中?

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1792092, encodeId=c70e1e92092ba, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Nov 03 07:31:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281256, encodeId=78dd1281256f3, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525692, encodeId=e1e7152569211, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545465, encodeId=cd2b15454654f, content=<a href='/topic/show?id=61d416e15a9' target=_blank style='color:#2F92EE;'>#SSRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16715, encryptionId=61d416e15a9, topicName=SSRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ea13741643, createdName=ms7474195563676018, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253352, encodeId=6bb625335256, content=5-ht会卒中?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Oct 16 09:11:46 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253287, encodeId=a2b325328ed9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 16 06:33:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253261, encodeId=e59a25326150, content=加大研究力度.造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cee2018203, createdName=1e207054m17(暂无匿称), createdTime=Mon Oct 16 02:08:59 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253244, encodeId=6c8725324475, content=不错学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Oct 16 00:08:15 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
    2017-10-16 yfjms

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1792092, encodeId=c70e1e92092ba, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Nov 03 07:31:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281256, encodeId=78dd1281256f3, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525692, encodeId=e1e7152569211, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545465, encodeId=cd2b15454654f, content=<a href='/topic/show?id=61d416e15a9' target=_blank style='color:#2F92EE;'>#SSRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16715, encryptionId=61d416e15a9, topicName=SSRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ea13741643, createdName=ms7474195563676018, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253352, encodeId=6bb625335256, content=5-ht会卒中?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Oct 16 09:11:46 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253287, encodeId=a2b325328ed9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 16 06:33:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253261, encodeId=e59a25326150, content=加大研究力度.造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cee2018203, createdName=1e207054m17(暂无匿称), createdTime=Mon Oct 16 02:08:59 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253244, encodeId=6c8725324475, content=不错学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Oct 16 00:08:15 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
    2017-10-16 1e207054m17(暂无匿称)

    加大研究力度.造福人类

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1792092, encodeId=c70e1e92092ba, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Nov 03 07:31:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281256, encodeId=78dd1281256f3, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525692, encodeId=e1e7152569211, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545465, encodeId=cd2b15454654f, content=<a href='/topic/show?id=61d416e15a9' target=_blank style='color:#2F92EE;'>#SSRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16715, encryptionId=61d416e15a9, topicName=SSRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ea13741643, createdName=ms7474195563676018, createdTime=Tue Oct 17 14:31:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253352, encodeId=6bb625335256, content=5-ht会卒中?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Oct 16 09:11:46 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253287, encodeId=a2b325328ed9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 16 06:33:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253261, encodeId=e59a25326150, content=加大研究力度.造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cee2018203, createdName=1e207054m17(暂无匿称), createdTime=Mon Oct 16 02:08:59 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253244, encodeId=6c8725324475, content=不错学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Oct 16 00:08:15 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
    2017-10-16 飛歌

    不错学习了很有用

    0

相关威廉亚洲官网

ASCP 2014:精神科药物或致儿童骨量流失和骨密度降低

一些研究表明,精神科药物与骨折具有较高的相关性,其中抗精神病药物与骨折呈现显著相关,还有一些研究表明,抗精神病药物与骨脆性增加所致骨折风险性增加之间存在一定关系。 在加拿大经过流行病学调查,对抗精神病药与精神疾病导致的骨质疏松性骨折的风险性进行了综合评估,发现抗精神病药为骨折疏松性骨折的危险因素。 一项呈现于2014年的美国临床精神药理学年会上的研究结果表明,儿童长期使用利培酮

BMJ:SSRIs与出生缺陷不相关

本研究使用国家出生缺陷预防研究中心的扩展数据集跟进先前报道的孕期使用SSRIs和具体的出生缺陷之间的相关性。 这是一项在美国10个中心进行的基于人群的多中心病例对照研究,使用贝叶斯分析方法对数据进行分析处理。研究人员通过出生证明或出生的医院对17952名有出生缺陷的患儿母亲和9857名无出生缺陷的患儿母亲(分娩时间1997-2009年)确定出生缺陷。在怀孕的三个月前使用艾司西酞普兰、氟西汀、帕罗

Stroke:SSRIs可能使出血性卒中恶化

一项丹麦研究显示,卒中发生前使用选择性5-羟色胺再摄取抑制剂(SSRIs)可能使部分患者事件恶化。 在出血性卒中患者中,症状出现前90天内使用1种SSRI与严重卒中(OR 1.41,95%CI:1.08~1.84)和30天内死亡(OR 1.60,95%CI:1.17~2.18)风险增加有关。然而,在缺血性卒中患者中,SSRIs使用与任何预后均无关。研究者为Janne Kaergaard Mort

Stroke:5-羟色胺再摄取抑制剂影响出血性卒中预后

卒中和抑郁的共病并非少见。5-羟色胺再摄取抑制剂(SSRIs)是临床上最常用的一线抗抑郁药之一。有研究显示,SSRIs会增高颅内出血的风险,亦有研究发现其对缺血性卒中具有神经保护作用。关于发病前应用SSRIs对卒中预后的影响,目前较少报道。 近期,丹麦奥胡斯大学的Mortensen教授等对全国(丹麦)2003年-2012年间登记在案的患者资料进行了一项回顾性队列研究,

Am J Psychiatry:胎儿期SSRIs暴露对婴儿生长无明显影响

    近期刊发于《美国精神病学杂志》(The American Journal of Psychiatry)网络版的一项前瞻性观察研究的结果显示,母亲孕期患有重度抑郁症或胎儿期选择性5-羟色胺再摄取抑制剂(SSRIs)暴露对婴儿出生后12个月内的体重、身长及头围增长无影响。   研究比较了出生第一年内,孕期重度抑郁症妇女所产婴儿,与孕期未接受